Medical

Theravance Biopharma has announced the initiation of a Phase 4 study of Yupelri revefenacin inhalation solution, which was approved by the FDA in 2018 for the treatment of COPD. The PIFR-2 study, which is expected to… Read more . . .

According to Quantum Leap Healthcare Collaborative (QLHC), a sponsor of the I-SPY COVID trial, interim analysis of data from a study of Genentech’s Pulmozyme dornase alfa inhalation solution for the treatment of severe COVID-19 found that… Read more . . .

Intranasal vaccine developer Intravacc and Leiden University Medical Center (LUMC) have announced a planned Phase 1/2 trial of LUMC’s Nanovac intranasal vaccine against coronaviruses, including SARS, MERS, and SARS-CoV-2. The trial is expected to begin… Read more . . .

According to Australian healthcare system Northern Health, the government of the state of Victoria will provide a $4.2 million grant to the University of Melbourne and Monash University to fund a clinical trial of intranasal… Read more . . .

Aridis Pharmaceuticals said that in vitro testing has demonstrated that its AR-701 monoclonal antibody (mAb) cocktail AR-701 has the ability to neutralize all SARS-CoV-2 variants, including Omicron, as well as the coronaviruses that cause SARS,… Read more . . .

Polyphor and EnBiotix have announced the initiation of Phase 1 trial of nebulized murepavadin in healthy volunteers; Polyphor had announced approval of a Phase 1 study by the MHRA in December 2020. The murepavadin inhalation… Read more . . .

Aerovate Therapeutics has initiated a Phase 2b/3 trial of its AV-101 imatinib DPI for the treatment of pulmonary arterial hypertension (PAH), the company said. The IMPAHCT trial is expected to enroll 462 PAH patients; the… Read more . . .

McMaster University announced that Health Canada has cleared a Phase 1 trial of two inhaled adenovirus vector vaccines against SARS-CoV-2, and the study is set to begin shortly. The trial is expected to enroll at… Read more . . .